This study is a prospective non-randomized study including 50 patients with established diagnosis of epithelial ovarian carcinoma attending Kasr El Einy Centre of Clinical Oncology (NEMROCK) in the period from January 2006 to December 2007 inclusive. After complete diagnosis and staging work up, the patients received either Paclitaxel 175 mg/m2 followed by Carboplatin AUC 5 (Arm A) or single agent Carboplatin AUC 7 (Arm B) for 6 cycles provided adequate response occured after 3 cycles as assessed by CA 125 and CT scan. At a median follow up period of 16.3 months, the median progression free survival was 10.8 months with a mean value of 23.18 months. About 60 % of patients showed no disease progression at 2 years. There was no statistically significant difference between the 2 arms in either the response rate or the progression free survival. Serum Vascular Endothelial Growth Factor at baseline seems to have no prognostic value with no correlation to either disease stage or outcome.